Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

This is a cohort screening study to prospectively identify the incidence of prostate cancer in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.

Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer risk consists of a PSA test and prostate physical examination beginning at age 50 years and if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the prostate is performed.

Inclusion Criteria:

• All men ≥30 years of age with at least a ten-year life expectancy
• A known BRCA2 mutation
• Ability to have an MRI
• Able to give informed consent will be approached to participate in the study

Exclusion Criteria:

• If a man has received or is currently receiving treatment for prostate cancer